Harnessing local and systemic immunity for vaccines against tuberculosis
- PMID: 24253104
- DOI: 10.1038/mi.2013.99
Harnessing local and systemic immunity for vaccines against tuberculosis
Abstract
The lung is the portal of entry for Mycobacterium tuberculosis (Mtb) and animal experimental evidence indicates that local immune defense mechanisms are crucial for protective immunity. Immunization via the lower respiratory tract efficiently induces a dividing, activated, antigen-dependent, lung-resident, memory T-cell population, which is partly recoverable by bronchoalveolar lavage. These cells can inhibit the growth of Mtb in the lungs immediately after infection. Delivery of appropriate signals to the lung innate immune system is critical for induction of effective local immunity. In contrast after parenteral immunization, antigen-specific cells may be found in lung tissue but few are recoverable by lavage and inhibition of mycobacterial growth is delayed. Harnessing both local and systemic immunity can provide highly effective protection in animal models and the evidence suggests that taken in aggregate, multiple animal models may predict the success of novel vaccine strategies in humans.
Similar articles
-
Natural and trained innate immunity against Mycobacterium tuberculosis.Immunobiology. 2020 May;225(3):151951. doi: 10.1016/j.imbio.2020.151951. Epub 2020 Apr 27. Immunobiology. 2020. PMID: 32423788 Review.
-
Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A.Vaccine. 2013 Feb 4;31(7):1086-93. doi: 10.1016/j.vaccine.2012.12.024. Epub 2012 Dec 21. Vaccine. 2013. PMID: 23262169 Free PMC article.
-
Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.Front Immunol. 2018 Oct 16;9:2371. doi: 10.3389/fimmu.2018.02371. eCollection 2018. Front Immunol. 2018. PMID: 30386336 Free PMC article.
-
CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.Infect Immun. 2011 Aug;79(8):3328-37. doi: 10.1128/IAI.01133-10. Epub 2011 May 31. Infect Immun. 2011. PMID: 21628524 Free PMC article.
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
Cited by
-
Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.Microorganisms. 2021 Apr 30;9(5):973. doi: 10.3390/microorganisms9050973. Microorganisms. 2021. PMID: 33946283 Free PMC article. Review.
-
Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity.Front Immunol. 2023 Dec 7;14:1306449. doi: 10.3389/fimmu.2023.1306449. eCollection 2023. Front Immunol. 2023. PMID: 38130713 Free PMC article.
-
Robust induction of TRMs by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses.Mol Ther Methods Clin Dev. 2021 Mar 23;21:299-314. doi: 10.1016/j.omtm.2021.03.010. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 33898629 Free PMC article.
-
Detection of live M. bovis BCG in tissues and IFN-γ responses in European badgers (Meles meles) vaccinated by oropharyngeal instillation or directly in the ileum.BMC Vet Res. 2019 Dec 6;15(1):445. doi: 10.1186/s12917-019-2166-4. BMC Vet Res. 2019. PMID: 31810466 Free PMC article.
-
Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis.mBio. 2016 Nov 22;7(6):e01686-16. doi: 10.1128/mBio.01686-16. mBio. 2016. PMID: 27879332 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical